Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Alona Zer, ASCO 2019 – Phase II study of nivolumab and ipilimumab in CKS

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 11th 2019

At the ASCO 2019 annual meeting, Alona Zer discusses the preliminary results from the interim analysis of a phase II study of nivolumab and ipilimumab in previously treated progressive Classic Kaposi Sarcoma (CKS) (NCT03219671).

Questions

1. Could you tell us a little about Classic Kaposi Sarcoma (CKS) and its prognosis? (0:04)
2. What is the rationale for using immune checkpoint inhibitors in patients with CKS? (0:35)
3. What are the limitations of current treatment options for CKS? (1:13)
4. What were the efficacy and safety findings of the phase II study investigating nivolumab and ipilimumab in patients with CKS? (1:50)
5. Which patients are most likely to respond to nivolumab plus ipilimumab? (02:37)

Speaker disclosure: Alona Zer has received a research grant and participated in an advisory board for BMS.

Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup